Affimed (Nasdaq: AFMD) is a German therapeutics company committed to utilizing the untapped potential of the innate immune system to restore patients’ natural ability to fight cancer.

Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing the company with one of the most mature pipelines in the innate immune oncology field. The company’s lead product candidate has demonstrated transformational data in patients suffering from end-stage Hodgkin’s lymphoma. If these results can be replicated, Affimed has the potential to lead a paradigm shift in oncology by offering a life-changing new treatment option for thousands of patients. In addition, Affimed’s second product candidate has shown very promising data in end-stage lung cancer patients, a group that is rapidly growing and for which treatment options are virtually non-existent. Affimed’s pipeline is based on its proprietary ROCK® platform, which enables the identification and destruction of tumors in a specific, targeted manner.

Gilde Healthcare followed Affimed’s development for many years prior to investment. By anchoring an upsized public offering of $103.5m in April 2022, Gilde enabled crucial financing in a turbulent market environment.